Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India

PISCATAWAY, N.J., [February 10, 2026] : Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company. The complex peptide product will be commercialized by Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe and the UK. The agreement covers pan-European, UK, and India...

News Reach
News Reach Verified Media or Organization • 11 Apr, 2026 Agency
February 10, 2026 • 3:37 PM  0
S
Sangri Today Spotlight
BREAKING
News Reach
News Reach
4 months ago
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India
cals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India
PISCATAWAY, N.J., [February 10, 2026] : Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company. The complex peptide product will be commercialized by Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe and the UK. The agreement covers pan-European, UK, and India...
Full Story: https://www.sangritoday.com/spotlight/kashiv-biosciences-and-intas-pharmaceuticals-sign-an-exclusive-licensing-and-supply-agreement-for-complex-peptide-product-in-europe-the-uk-india
https://www.sangritoday.com/spotlight/kashiv-biosciences-and-intas-pharmaceuticals-sign-an-exclusive-licensing-and-supply-agreement-for-complex-peptide-product-in-europe-the-uk-india
Google News
Copied
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India

PISCATAWAY, N.J., [February 10, 2026] : Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company. The complex peptide product will be commercialized by Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe and the UK.

The agreement covers pan-European, UK, and India markets. Under the terms of the agreement, Kashiv will be responsible for the regulatory registration, manufacturing and supply of the product, while Accord will manage the commercialization and distribution across the regions.

favorite Follow us for the latest updates:

News Reach Verified Media or Organization • 11 Apr, 2026 Agency

NewsReach offers an efficient and effective solution for publishing press releases.

home Home amp_stories Web Stories local_fire_department Trending play_circle Videos mark_email_unread Newsletter